Targeted nanoparticles incorporating siRNA offer promise for cancer treatment

May 20, 2007

The use of targeted nanoparticles offers promising techniques for cancer treatment. Researchers in the laboratory of Mark E. Davis at the California Institute of Technology have been using small interfering RNA (siRNA), sometimes known as silencing RNA, to "silence" specific genes that are implicated in certain malignancies.

One of the primary challenges associated with this type of therapy is delivering the therapeutic agent into the body and then to the tumor in a safe and effective manner. By using targeted nanoparticles, researchers have demonstrated that systemically delivered siRNA can slow the growth of tumors in mice without eliciting the toxicities often associated with cancer therapies. The results of this research are being presented this week at the NSTI Nanotech 2007 Conference in Santa Clara, CA.

The Caltech researchers have incorporated siRNA into nanoparticles that are formed completely by self-assembly, characterized the behavior of these nanoparticles and studied their safety and efficacy in mice.

Using extensive physicochemical and biological characterization, the investigators are able to estimate the composition of individual nanoparticles and to correlate the nanoparticle structure with its biological function. This quantitative approach provides unique insights into the design of more effective nanoparticle carriers.

According to the lead author of the study, Derek W. Bartlett, "Safe and effective delivery remains perhaps the greatest impediment to the clinical realization of small interfering RNA (siRNA) in cancer therapy. Formation of siRNA nanoparticles using cyclodextrin-containing polycations is one of the most promising strategies for systemic siRNA delivery, and such nanoparticles are expected to enter Phase I clinical trials by late 2007. Our most recent work examines the impact of various dosing schedules and surface modifications on the efficacy of these siRNA nanoparticles in preclinical cancer models. By combining the experimental data with a mathematical model of siRNA-mediated gene silencing, we illustrate several practical considerations that we believe will be directly relevant to the clinical application of siRNA-based therapeutics in cancer therapy."

Source: Elsevier Health Sciences

Explore further: PRINTed nanoparticles deliver multiple punches to treat prostate cancer

Related Stories

Understanding how cells respond to nanoparticles

October 28, 2010

Gold nanoparticles are showing real promise as vehicles for efficiently delivering therapeutic nucleic acids, such as disease-fighting genes and small interfering RNA (siRNA) molecules, to tumors. Now, a team of investigators ...

Recommended for you

Physicists develop new technique to fathom 'smart' materials

November 26, 2015

Physicists from the FOM Foundation and Leiden University have found a way to better understand the properties of manmade 'smart' materials. Their method reveals how stacked layers in such a material work together to bring ...

Mathematicians identify limits to heat flow at the nanoscale

November 24, 2015

How much heat can two bodies exchange without touching? For over a century, scientists have been able to answer this question for virtually any pair of objects in the macroscopic world, from the rate at which a campfire can ...

New sensor sends electronic signal when estrogen is detected

November 24, 2015

Estrogen is a tiny molecule, but it can have big effects on humans and other animals. Estrogen is one of the main hormones that regulates the female reproductive system - it can be monitored to track human fertility and is ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.